Abstract:e15046 Background: It has been demonstrated that epithelial growth factor receptor (EGFR) is overexpressed in 30-80% of esophageal cancer (EC). Therefore, the selection of potential population who could benefit from this treatment is of great importance. We analyzed the EGFR expression by immunohistochemical staining in advanced or metastatic esophageal squamous cell carcinoma (ESCC) patients who received combination treatment of nimotuzumab with chemotherapy to explore the correlation of the EGFR protein expression with the clinical response. Methods: The patients enrolled in this study were from a prospective phase II clinical trial of “Nimotuzumab plus paclitaxel and cisplatin as 1st line treatment for esophageal squamous cell cancer: a single centre prospective clinical trial” (NCT01336049). The tumor tissues were obtained from either gastroscopic biopsy or surgical removed mass. The expression of EGFR was detected by standard immunohistochemical stain methods. The high EGFR expression was defined as strong and continuous membrane staining in more than 50% cells. Results: Totally 55 tumor tissues of ESCC patients were analyzed. 18 of 55 (32.7%) were with high EGFR expression while the other 37 cases were with low to moderate EGFR expression. The expression of EGFR had no relation with the sex, age, tumor location, and tumor differentiation. The objective response rate in EGFR high expression group was 55.6% while that in EGFR low to moderate was 54.1% (p=0.6). The median progression-free survival in EGFR high expression group was much shorter than that in EGFR low to moderate expression group (5.9±1.3 months vs 11.0±3.1 months, P=0.047). The median overall survival in EGFR high expression group was also shorter than that in the EGFR low to moderate expression group (9.7±0.5 months vs 21.5±1.5 months, P=0.037). Conclusions: The overexpression of EGFR could not predict the ORR of the combination of nimotuzumab with chemotherapy. But the high expression of EGFR was associated with poor PFS and OS. It implied that EGFR expression might be a predictor of disease prognosis but not a predictor of the outcome of anti-EGFR agent, nimotuzumab, teatment.

Cyclin A overexpression is associated with chemosensitivity to paclitaxel-based chemotherapy in patients with esophageal squamous cell carcinoma.

Prognostic value of PD-L1 expression on immune cells or tumor cells for locally advanced esophageal squamous cell carcinoma in patients treated with neoadjuvant chemoradiotherapy

Efficacy of Paclitaxel Plus Cisplatin in Advanced Esophageal Squamous Cell Cancer: Further Analysis of Single Center, Prospective Study.

Cyclin A1 expression and paclitaxel resistance in human ovarian cancer cells

Prognostic factors of metastatic or recurrent esophageal squamous cell carcinoma in patients receiving three-drug combination chemotherapy.

Overexpression of Cyclin B1 Antagonizes Chemotherapeutic-Induced Apoptosis Through Pten/Akt Pathway in Human Esophageal Squamous Cell Carcinoma Cells

CDK4 Amplification in Esophageal Squamous Cell Carcinoma Associated with Better Patient Outcome

The clinical significance of p53 and pRb signal pathway in esophageal cancer patients

Increased HOXC6 Expression Predicts Chemotherapy Sensitivity in Patients with Esophageal Squamous Cell Carcinoma.

First-Line Paclitaxel and Cisplatin in Patients with Advanced Squamous-Cell Carcinoma of the Esophagus

Impact of Cyclin E on Sensitivity of Taxane-Containing Chemotherapy and Prognosis in the Patients with Advanced Breast Cancer

Chemoradiotherapy with Paclitaxel Liposome Plus Cisplatin for Locally Advanced Esophageal Squamous Cell Carcinoma: A Retrospective Analysis

Clinicopathological Significance of Cyclooxygenase-2 and Cell Cycle-Regulatory Proteins Expression in Patients with Esophageal Squamous Cell Carcinoma.

Genome-scale CRISPR Activation Screening Identifies a Role of ELAVL2-CDKN1A Axis in Paclitaxel Resistance in Esophageal Squamous Cell Carcinoma.

Possible prediction of the response of esophageal squamous cell carcinoma to neoadjuvant chemotherapy based on gene expression profiling.

Study of Single Nucleotide Polymorphisms of FBW7 and Its Substrate Genes Revealed a Predictive Factor for Paclitaxel Plus Cisplatin Chemotherapy in Chinese Patients with Advanced Esophageal Squamous Cell Carcinoma

Cyclin D1 Expression Predicts Postoperative Distant Metastasis And Survival In Resectable Esophageal Squamous Cell Carcinoma

Single-cell Transcriptome Analyses Reveal Molecular Signals to Intrinsic and Acquired Paclitaxel Resistance in Esophageal Squamous Cancer Cells

The Expression of EGFR by Immunohistochemical Staining to Predict the Response of Nimotuzumab in Esophageal Squamous Cell Carcinoma.

Expression of Cyclin D1 Protein in Stage T2-3N0M0 Esophageal Carcinoma and Its Relationship with Prognosis

Dissecting the single-cell transcriptome network in patients with esophageal squamous cell carcinoma receiving operative paclitaxel plus platinum chemotherapy